SAHPRA is monitoring the supply chain as well as the online platforms for unregistered, substandard, and falsified medicines containing or claiming to contain GLP-1 Substances, indicated SAHPRA CEO, Dr Boitumelo Semete Makokotlela
Some of those lawsuits have been filed by past Wegovy patients who say the medication caused them to suffer from vision problems, and they were not aware that this was a potential side effect
Protocols involving AOD-9604 with tirzepatide , NAD+ with tirzepatide , or cagrilintide with semaglutide may alter appetite patterns differently
The gap looks real, but it isnt the clean apples-to-apples race it gets sold as, so dont treat it like one
WA William A
Building on the understanding that GLP-1 agonists induce weight loss through appetite suppression and slowed gastric emptying, it is crucial to recognize the potential downstream consequences of these mechanisms, particularly regarding nutritional status